Sarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Buy at StockNews.com

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

Several other research analysts also recently commented on the company. Piper Sandler decreased their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James reaffirmed an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Finally, UBS Group increased their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Buy” and an average price target of $181.33.

Sarepta Therapeutics Stock Down 3.0 %

SRPT stock traded down $3.52 during midday trading on Tuesday, hitting $114.32. The stock had a trading volume of 1,110,094 shares, compared to its average volume of 1,233,550. Sarepta Therapeutics has a 52-week low of $76.61 and a 52-week high of $173.25. The firm has a market cap of $10.92 billion, a price-to-earnings ratio of 91.46 and a beta of 0.81. The business has a 50-day moving average of $125.56 and a two-hundred day moving average of $132.90. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.19.

Insiders Place Their Bets

In related news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $607,000. Teachers Retirement System of The State of Kentucky bought a new position in Sarepta Therapeutics during the 2nd quarter worth $4,771,000. Securian Asset Management Inc. bought a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $1,187,000. Natixis Advisors LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter worth $1,918,000. Finally, Oppenheimer Asset Management Inc. grew its position in Sarepta Therapeutics by 32.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 874 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.